Navigation Links
Elbit Imaging Ltd. Announces Second Quarter Results for 2012
Date:8/30/2012

TEL AVIV, Israel, August 30, 2012 /PRNewswire/ --

Elbit Imaging Ltd. (TASE,NASDAQ: EMITF) ("Elbit" or the "Company") announced today its results for the second quarter of 2012.

Three months ended June 30,2012 compared to corresponding period in 2011

Consolidated revenues for the three months period ended June 30, 2012 amounted to NIS 231 million (US$ 59 million) compared to NIS 241 million in the corresponding period in 2012.

The revenues are affected by: (i) an increase in revenues from commercial centers, mainly attributable to the opening of additional three centers and the sale of office space in India by our subsidiary, Plaza Centers; (ii) an increase in revenues from sale of medical systems by InSightec; and (iii) gain from sale of the retail activity of GAP in April 2012, offset by: (i) a decrease in revenues from hotels, attributable to the sale of the Company's share in four Dutch hotels in March 2012; (ii) a decrease in revenues from the retail activity, attributable to the sale of GAP in April 2012; (iii) a decrease in gain from fair value adjustment of investment property in the US which was reported in the corresponding period in 2011. These assets were sold in June 2012.

  • Revenues from commercial centers increased in Q2 2012 to NIS 59 million (US$ 15 million) compared to NIS 27 million in Q2 2011. The increase is mainly attributable to the operation of seven commercial centers in Q2 2012 compared to the operation of four commercial centers in Q2 2011 and to the sale of office space in India for the first time.
  • Cost of commercial centers increased in Q2 2012 to NIS 49 million (US$ 12.5 million) compared to NIS 35 million in Q2 2011. The increase is attributable mainly to the increase in the revenues of three commercial centers and to the sale of office space in India, as aforementioned.
  • Revenues from investment property rental income (US) increased in Q2 2012 to NIS 63 million (US$ 16 million) compared to NIS 60 million in Q2 2011. The increase is mainly attributable to growth in occupancy in the investment property during the period.
  • Cost of investment property in Q2 2012 amounted to NIS 24 million (US$ 6 million) similar to NIS 25 million in Q2 2011.
  • Cost of fair value adjustment and sell of investment property in Q2 2012 amounted to NIS 104 million (US$ 26.5 million) compared to revenues in the amount of NIS 25 million in Q2 2011. The current net costs include the costs derived from the transaction sale of 47 out of 49 US properties, their fair value adjustment and realization of foreign currency translation adjustments reserve.
  • Revenues from hotels operation and management decreased in Q2 2012 to NIS 55 million (US$ 14 million) compared to NIS 79 million in Q2 2011. The decrease is mainly attributable to the sale of the Company's hotels in the Netherlands in March 2012 as aforementioned, offset by the increase in the Company's revenues from the Romanian and Belgian hotels.
  • Costs and expenses of hotels operation and management decreased in Q2 2012 to NIS 49 million (US$ 12.5 million) compared to NIS 64 million in Q2 2011. The decrease is attributable mainly to the sale of the Company's hotels in the Netherlands in March 2012, as aforementioned.
  • Revenues from the sale of medical systems increased in Q2 2012 to NIS 14 million (US$ 3.6 million) compared to NIS 5 million in Q2 2011. The increase is mainly attributable to the number of systems sold during the period.
  • Costs and expenses of medical systems decreased in Q2 2012 to NIS 16 million (US$ 4 million) compared to NIS 19 million in Q2 2011. The decrease in costs is mainly attributable to the cost saving measures applied by InSightec in the second half of 2011 and to the decrease in legal related expenses.
  • Research and development expenses decreased in Q2 2012 to NIS 11 million (US$ 3 million) compared to NIS 16 million in Q2 2011. The decrease in costs is attributable to cost saving measures applied by InSightec in the second half of 2011 and to the decrease in expenses for clinical treatments.  
  • Revenues from the sale of fashion retail decreased in Q2 2012 to NIS 33 million (US$ 8 million) compared to NIS 46 million in Q2 2011. The decrease is mainly attributable to the sale of the retail activity of GAP in April 2012, as aforementioned, partially offset by the increase in the revenues attributable to the activity of Mango.
  • Cost of fashion retail decreased in Q2 2012 to NIS 33 million (US$ 8 million) compared to NIS 52 million in Q2 2011. The decrease is mainly attributable to the sale of the retail activity of GAP, as aforementioned.
  • General and administrative expenses decreased in Q2 2012 to NIS 11 million (US$ 3 million) compared to NIS 18 million in Q2 2011. General and administrative expenses excluding noncash expenses amounted to NIS 8 million (US$ 2 million) in Q2 2012 compared to NIS 12 million in Q2 2011. The decrease in cash expenses is attributable to the continuing cost saving measures taken this year with respect to payroll expenses and other expenses.
  • Financial expenses, net increased in Q2 2012 to NIS 74 million (US$ 19 million) compared to NIS net financial income of 26 million in Q2 2011. The increase of NIS 100 million is mainly attributable to the following:
    • An increase in the amount of NIS 81 million (US$ 20.6 million) in noncash expenses, as a result of changes in fair value of financial instruments (mainly Plaza Centers' debentures, call transactions, other derivatives and marketable securities, which are measured at fair value through profit and loss).
    • An increase in interest expenses, net in the amount of NIS 19 million (US$ 5 million) mainly attributable to an increase in the interest expenses related to the activity of Plaza Centers' commercial centers.
  • Other revenues, net in Q2 2012 amounted to NIS 3 million (US$ 0.8 million) compared to expenses in the amount of NIS 23 million in Q2 2011.
  • Loss for Q2 2012 amounted to NIS 132 million (US$ 33.6 million) (out of which NIS 141 is attributed to the equity holders of the Company) compared to gain in the amount of NIS 14 million in the corresponding period in 2011 (out of which a loss in the amount of NIS 30 million is attributed to the equity holders of the Company).
  • Cash and cash equivalents as of June 30, 2012 amounted to NIS 1.5 billion (US$ 380 million) compared to NIS 0.6 billion as of December 31, 2011. The increase is attributable to the sale of 47 out of 49 US investment properties and to the sale of four Dutch hotels, as aforementioned.

  • Shareholders' equity as of June 30, 2012 amounted to NIS 1.7 billion (US$ 430 million) (out of which NIS 0.4 billion is attributed to the equity holders of the Company) compared to NIS 1.5 billion (out of which NIS 0.4 billion is attributed to the equity holders of the Company) as of December 31, 2011. In the current quarter, the Company has initially implemented the revaluation model with respect to the Company's property, plant and equipment (mainly the hotels segment), which contributed to an increase in the Company's equity.

Our presentation to the consolidated financial statements for the second quarter of 2012 is available through our website at: http://www.elbitimaging.com under: "Investor Relations - Company Presentations (06/2012)."

 

About Elbit Imaging Ltd.


Elbit Imaging Ltd. operates in the following principal fields of business: (i) Commercial and Entertainment Centers - Initiation, construction and sale of shopping and entertainment centers and other mixed-use real property projects, predominantly in the retail sector, located in Central and Eastern Europe and in India, primarily through its subsidiary Plaza Centers N.V. In certain circumstances and depending on market conditions, we operate and manage commercial and entertainment centers prior to their sale; (ii) U.S. Real Property - Investment in commercial real property in the United States; (iii) Hotels - Hotel operation and management; (iv) Medical Industries - (a) research and development, production and marketing of magnetic resonance imaging guided focused ultrasound treatment equipment and (b) development of stem cell population expansion technologies and stem cell therapy products for transplantation and regenerative medicine; (v) Residential Projects - Initiation, construction and sale of residential projects and other mixed-use real property projects, predominately residential, located primarily in India; (vi) Fashion Apparel - Distribution and marketing of fashion apparel and accessories in Israel; and (vii) Other Activities - (a) venture capital investments and (b) potential investments in hospitals and farm and dairy plants in India. We have presently decided to suspend our investment activities in hospitals and farm and dairy plants in India until we are satisfied that the economy has recovered sufficiently to resume such activities.

Any forward-looking statements in our releases include statements regarding the intent, belief or current expectations of Elbit Imaging Ltd. and our management about our business, financial condition, results of operations, and its relationship with its employees and the condition of our properties. Words such as "believe," "expect," "intend," "estimate" and similar expressions are intended to identify forward-looking statements but are not the exclusive means of identifying such statements. Actual results may differ materially from those projected, expressed or implied in the forward-looking statements as a result of various factors including, without limitation, the factors set forth in our filings with the Securities and Exchange Commission including, without limitation, Item 3.D of our annual report on Form 20-F for the fiscal year ended December 31, 2011, under the caption "Risk Factors." Any forward-looking statements contained in our releases speak only as of the date of such release, and we caution existing and prospective investors not to place undue reliance on such statements. Such forward-looking statements do not purport to be predictions of future events or circumstances, and therefore, there can be no assurance that any forward-looking statement contained our releases will prove to be accurate. We undertake no obligation to update or revise any forward-looking statements.  


ELBIT IMAGING LTD.

CONSOLIDATED BALANCE SHEETS

June 30 December 31 June 30 2 0 1 2 2 0 1 1 2 0 1 2 Convenience translation (in NIS thousands) US$'000 Current Assets Cash and cash equivalents 1,522,638 602,292 388,131 Short-term deposits and investments 251,905 409,338 64,212 Trade accounts receivable 56,013 72,049 14,278 Other receivables 103,402 101,566 26,357 Prepayments and other assets 262,703 262,861 66,965 Inventories 31,897 48,043 8,131 Trading property 4,591,485 4,556,616 1,170,401 6,820,043 6,052,765 1,738,475 Held for sale investment property 74,391 - 18,963 6,894,434 6,052,765 1,757,438 Non-Current Assets Deposits, loans and other long-term balances 129,451 380,077 32,998 Investments in associates 17,958 10,556 4,578 Property, plant and equipment 1,229,297 1,167,646 313,356 Investment property 115,165 2,672,571 29,356 Other assets and deferred expenses 11,544 13,037 2,943 Intangible assets 43,852 74,415 11,178 1,547,267 4,318,302 394,409 8,441,701 10,371,067 2,151,847 Current Liabilities Short-term credits 780,532 1,079,736 198,963 Borrowings relating to trading property 1,203,723 1,124,031 306,836 Suppliers and service providers 102,041 219,229 26,010 Payables and other credit balances 408,155 261,744 104,040 Other liabilities 142,801 157,144 36,400 2,637,252 2,841,884 672,249 Liabilities associated with investment property held for sale 23,717 - 6,047 Liabilities related to discontinued operation 3,401 2,941 868 2,664,370 2,844,825 679,164 Non-Current liabilities Borrowings 3,877,797 5,650,170 988,478 Other financial liabilities 97,308 215,752 24,805 Other liabilities 12,151 12,808 3,098 Deferred taxes 129,375 108,642 32,978 4,116,631 5,987,372 1,049,359 Shareholders' Equity Attributable to equity holders of the Company 413,765 359,630 105,472 Non-controlling interest 1,246,935 1,179,240 317,852 1,660,700 1,538,870 423,324 8,441,701 10,371,067 2,151,847

ELBIT IMAGING LTD.

CONSOLIDATED INCOME STATEMENTS

Three months Year Six months Six months ended ended ended ended December June 30 June 30 31, June 30 2 0 1 2 2 0 1 1 2 0 1 2 2 0 1 1 2 0 1 1 2 0 1 2 (in NIS thousands) Convenience translation US$'000 Revenues and gains Gain from sale of property plant and equipment 53,875 - - - - 13,733 Gains from changes and sale of shareholding in investees entities 7,801 - 7,801 - 15,450 1,988 Commercial centers 98,557 55,667 59,150 26,519 115,270 25,123 Gain from fair value adjustment of investment property - 49,785 - 24,974 100,818 - Investment property rental income 133,640 121,774 62,906 60,448 254,806 34,066 Hotels operations and management 117,807 138,147 54,527 78,912 286,548 30,030 Sale of medical systems 28,529 13,118 13,829 4,562 53,324 7,272 Sale of fashion merchandise and other 74,641 83,588 32,947 45,580 185,082 19,027 514,850 462,079 231,160 240,995 1,011,298 131,239 Expenses and losses Commercial centers 91,303 74,380 49,200 35,399 159,626 23,274 Investment property expenses 58,063 51,326 23,742 25,008 112,262 14,801 Expenses relating to realization of investment property, net of gain from fair value adjustment 103,696 - 103,696 - - 26,433 Hotels operations and management 108,150 117,732 48,722 64,402 240,784 27,568 Cost and expenses of medical systems operation 31,449 36,398 16,167 18,667 101,498 8,016 Cost of fashion merchandise and other 83,291 97,583 32,626 52,413 211,743 21,231 Research and development expenses 22,816 32,377 10,576 15,936 62,851 5,816 General and administrative expenses 24,641 32,310 11,075 17,635 61,857 6,281 Share in losses of associates, net 4,582 3,877 1,743 1,860 7,568 1,168 Financial expenses (income), net 225,139 9,501 74,397 (26,037) (86,560) 57,390 Write down, charges and other expenses (income), net 23,197 36,583 (2,673) 22,579 309,885 5,913 776,327 492,067 369,271 227,862 1,181,514 197,891 Profit (loss) before income taxes (261,477) (29,988) (138,111) 13,133 (170,216) (66,652) Income tax expenses (tax benefit) (5,662) (2,201) (5,760) (498) 86,550 (1,443) Profit (loss) from continuing operations (255,815) (27,787) (132,351) 13,631 (256,766) (65,209) Profit from discontinued operation, net - - - - 9,737 - Profit (loss) for the period (255,815) (27,787) (132,351) 13,631 (247,029) (65,209) Attributable to: Equity holders of the Company (228,940) (93,507) (141,227) (30,212) (264,919) (58,359) Non-controlling interest (26,875) 65,720 8,876 43,843 17,890 (6,850) (255,815) (27,787) (132,351) 13,631 (247,029) (65,209)


ELBIT IMAGING LTD.

CONSOLIDATED COMPREHENSIVE INCOME STATEMENTS

Six months Three months Year Six months ended ended ended ended December June 30 June 30 31, June 30 2 0 1 2 2 0 1 1 2 0 1 2 2 0 1 1 2 0 1 1 2 0 1 2 (in NIS thousands) Convenience translation US$'000 Profit (loss) for the period (255,815) (27,787) (132,351) 13,631 (247,029) (65,209) Exchange differences arising from translation of foreign operations (35,878) 26,842 (25,832) (64,922) 38,031 (9,146) Loss from cash flow hedge (7,181) - (16,023) - (41,577) (1,830) Gain (loss) from available for sale investments 2,117 543 (3,520) 55 (4,131) 540 Initial adaption of the revaluation model (with respect to hotels) 408,484(*) - 30,548 - - 104,125 Loss on hedging instruments designated in hedges of the net assets of foreign operations 38,643 - 38,642 - - 9,850 Reclassification of adjustments relating to foreign operations disposed of in the year (75,610) - (75,610) - - (19,273) 330,575 27,385 (51,795) (64,867) (7,677) 84,266 Comprehensive income (loss) 74,760 (402) (184,146) (51,236) (254,706) 19,057 Attributable to: Equity holders of the Company 58,132 (65,245) (118,609) (71,209) (264,454) 14,816 Non-controlling interest 16,628 64,843 (65,537) 19,973 9,748 4,241 74,760 (402) (184,146) (51,236) (254,706) 19,057

(*)    Net of related tax expenses in the amount of NIS 97 million.

ELBIT IMAGING LTD.

STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY

Foreign Revaluation currency Other of property Stock based Share Share translation reserves plant and compensation Capital premium reserve (*) equipment reserve (in thousand NIS) Balance - December 31, 2010 38,051 844,574 (471,993) (33,904) - 57,201 Loss for the year - - - - - - Comprehensive income (loss) - - 42,876 (42,411) - - Dividend paid to the non-controlling interest by a subsidiary - - - - - - Stock based compensation expenses - - - - - 10,705 Exercise of shares by employees 8 20,237 - - - (20,245) Initially consolidated subsidiary - - - - - - Purchase of unit holdings from Non-controlling interest by a subsidiary - - - (155,102) - - Issuance of shares to the non-controlling interest by a subsidiary - - - 7,741 - - Balance - December 31, 2011 38,059 864,811 (429,117) (223,676) - 47,661 Loss for the period - - - - - - Comprehensive income (loss) - - (82,436) 34,934 (**)195,189 - Stock based compensation expenses - - (313) - - 2,121 Transaction with Non-controlling interest - - - (5,805) - - Balance - June 30, 2012 38,059 864,811 (511,866) (194,547) 195,189 49,782

Table continued…

Attributable to Non- Total Retained Gross Treasury shareholders controlling shareholders' earnings amount stock of the Company Interest equity (in thousand NIS) Balance - December 31, 2010 495,332 929,261 (168,521) 760,740 1,416,781 2,177,521 Loss for the year (264,919) (264,919) - (264,919) 17,890 (247,029) Comprehensive income (loss) 465 - 465 (8,142) (7,677) Dividend paid to the non-controlling interest by a subsidiary - - - - (56,529) (56,529) Stock based compensation expenses - 10,705 - 10,705 36,278 46,983 Exercise of shares by employees - - - - - - Initially consolidated subsidiary - - - - 11,766 11,766 Purchase of unit holdings from Non-controlling interest by a subsidiary - (155,102) - (155,102) (226,634) (381,736) Issuance of shares to the non-controlling interest by a subsidiary - 7,741 - 7,741 (12,170) (4,429) Balance - December 31, 2011 230,413 528,151 (168,521) 359,630 1,179,240 1,538,870 Loss for the period (228,940) (228,940) (228,940) (26,875) (255,815) Comprehensive income (loss) (***)139,385 287,072 - 287,072 43,503 330,575 Stock based compensation expenses - 1,808 - 1,808 36,272 38,080 Transaction with Non-controlling interest - (5,805) - (5,805) 14,795 8,990 Balance - June 30, 2012 140,858 582,286 (168,521) 413,765 1,246,935 1,660,700

(*)    Includes with non-controlling interest and hedging reserve.

(**)    Net of related tax expenses in the amount of NIS 40 million.

(***)    Net of related tax expenses in the amount of NIS 45 million.

ELBIT IMAGING LTD.

STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY

Foreign Revaluation currency Other of property Stock based Share Share translation reserves plant and compensation Capital premium reserve (*) equipment reserve (in thousand US$) Balance - December 31, 2011 9,701 220,446 (109,385) (57,016) - 12,149 Loss for the period - - - - - - Comprehensive income (loss) - - (21,015) 8,904 (**)49,755 - Stock based compensation expenses - - (78) - - 541 Transaction with non-controlling interest - - - (1,479) - - Balance - June 30, 2012 9,701 220,446 (130,478) (49,591) 49,755 12,690

Table continued…

Attributable to Non- Total Retained Gross Treasury shareholders controlling shareholders' earnings amount stock of the Company Interest equity (in thousand US$) Balance - December 31, 2011 58,734 134,629 (42,957) 91,672 300,597 392,269 Loss for the period (58,359) (58,359) - (58,359) (6,850) (65,209) Comprehensive income (loss) (***)35,531 73,175 - 73,175 11,091 84,266 Stock based compensation expenses - 463 - 463 9,242 9,705 Transaction with non-controlling interest - (1,479) - (1,479) 3,772 2,293 Balance - June 30, 2012 35,906 148,429 (42,957) 105,472 317,852 423,324

(*)    Includes with non-controlling interest and hedging reserve.

(**)    Net of related tax expenses in the amount of USD10 million.

(***)    Net of related tax expenses in the amount of USD11 million.


For Further Information:

Company Contact:
Mordechay Zisser
Chief Executive Officer (CEO
Tel: +972-3-608-6000
Motti@elbitimaging.com

Investor Contact:
Mor Dagan
Investor Relations
Tel: +972-3-516-7620
mor@km-ir.co.il  



'/>"/>
SOURCE Elbit Imaging Ltd.
Copyright©2012 PR Newswire.
All rights reserved


Related medicine technology :

1. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
2. ProUroCare Medical Receives FDA Clearance for ProUroScan Elasticity Imaging System
3. U.S. Patent Office Issues Sixth Patent Covering Zero-Footprint Medical Image Viewers to Heart Imaging Technologies, LLC
4. Boston Scientific and Philips Healthcare Announce Collaboration to Enhance Imaging Equipment Offering
5. Real Time Medical to Feature Diagnostic Imaging Software @ Innovation Showcase at e-Health 2012
6. ClearCanvas Partners With DPR to Offer CaseReader™, an Integrated Technology Structured Reporting Solution for Medical Imaging Professionals
7. Philips demonstrates innovations in nuclear medicine imaging with a comprehensive portfolio of NM applications for IntelliSpace Portal
8. Global Market for Medical Imaging Equipment to Reach $25.3 Billion as Retiring Boomers and Emerging Markets Demand Better Healthcare
9. IMD Adds Substantial Imaging Contracts
10. ICON Medical Imaging Selects AG Mednet to Give Clinical Trial Sponsors Zero-Delay Efficiency and Faster Decision-Making Results
11. Derry Medical and Derry Imaging Select Calypso for Website Redesign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Calif. , June 24, 2016  Global ... a biopharmaceutical company developing novel therapeutics for the ... needs, today announced the closing of its previously ... common stock, at the public offering price of ... the offering were offered by GBT. GBT estimates ...
(Date:6/24/2016)... June 24, 2016 Dehaier Medical Systems Ltd. ... which develops, markets and sells medical devices and wearable ... signed a strategic cooperation agreement with Hongyuan Supply Chain ... Chain") on June 20, 2016, to develop Dehaier,s new ... cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s sales ...
(Date:6/24/2016)... Belgium , June 24, 2016 /PRNewswire/ ... announced the appointment of Dr. Edward Futcher ... a Non-Executive Director, effective June 23, 2016.Dr. Futcher ... and Nominations and Governance Committees.  As a non-executive ... provide independent expertise and strategic counsel to VolitionRx ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... ... 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 ... by their peers for this recognition are considered among the top 2 percent of ... honors as members of this year’s Legal Elite Hall of Fame: Miami Shareholders ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening ... Talker Award, an essay contest in which patients and their families pay tribute to ... at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this ...
(Date:6/24/2016)... ... 2016 , ... Strategic Capital Partners, LLC (SCP) in concert ... capital for emerging technology companies. SCP has delivered investment events and professional ... than a million dollars of capital investment for five companies. The ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... supporting the upcoming 2016 Miss Arizona pageant as its official Medspa Sponsor. Dr. ... Tempe, Mesa, and Chandler, Arizona. , Dr. Olson says the decision to ...
Breaking Medicine News(10 mins):